Advanced NSCLC with other oncogenic addictions (BRAF, HER2, MET, RET, NRTK…)

Precision medicine has become a standard of care for patients with metastatic nonsmall cell lung cancer, particularly for the most common subtype, adenocarcinoma. Systematic early molecular profiling has revolutionized treatment for patients harboring genomic alteration, by targeting different oncogenic drivers, such as EGFR, ALK or ROS1. Over the past years new oncogenic drivers have emerged, such as BRAF, MET, RET, HER2, NTRK ou NRG1, which are actionable. Herein, we synthetize different therapeutic options targeting these drivers. These alterations are rare, but early identification may change therapeutic decision, with promising anti-tumor responses.